Celgene takeover of Pharmion clears antitrust hurdle
Jan 3 (Reuters) - Celgene Corp (CELG.O: Quotazione) said its proposed $2.9 billion acquisition of Pharmion Corp PHRM.O cleared an antitrust hurdle.
The 30-day waiting period under the Hart-Scott-Rodino Act had expired without the U.S. Federal Trade Commission requesting additional information, the company said in a statement.
The companies expect the transaction to close in April. (Reporting by Sharangdhar Limaye in Bangalore; Editing by Deepak Kannan)
© Thomson Reuters 2017 Tutti i diritti assegna a Reuters.